| Holly Neves, APRN | |
|
188 Route 101, Bedford, NH 03110-5451 | |
| (603) 663-8052 | |
| Not Available |
| Full Name | Holly Neves |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 188 Route 101, Bedford, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487013140 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 057915-23 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Catholic Medical Center | Manchester, NH | Hospital |
| Elliot Hospital | Manchester, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Catholic Medical Center | 6103897129 | 248 |
News Archive
Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.
An investigation published in the current issue of Psychotherapy and Psychosomatics indicates how the smartphone may have a potential in the treatment of insomnia.
A new method for detecting abnormalities in unborn children is providing physicians with more information to analyze the results than conventional, microscopic testing, according to two George Washington University researchers.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 4 days ago
| Entity Name | Catholic Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265487755 PECOS PAC ID: 6103897129 Enrollment ID: O20060801000310 |
News Archive
Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.
An investigation published in the current issue of Psychotherapy and Psychosomatics indicates how the smartphone may have a potential in the treatment of insomnia.
A new method for detecting abnormalities in unborn children is providing physicians with more information to analyze the results than conventional, microscopic testing, according to two George Washington University researchers.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 4 days ago
| Entity Name | Catholic Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972559904 PECOS PAC ID: 6103897129 Enrollment ID: O20060801000346 |
News Archive
Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.
An investigation published in the current issue of Psychotherapy and Psychosomatics indicates how the smartphone may have a potential in the treatment of insomnia.
A new method for detecting abnormalities in unborn children is providing physicians with more information to analyze the results than conventional, microscopic testing, according to two George Washington University researchers.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Holly Neves, APRN 188 Route 101, Bedford, NH 03110-5451 Ph: (603) 663-8052 | Holly Neves, APRN 188 Route 101, Bedford, NH 03110-5451 Ph: (603) 663-8052 |
News Archive
Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.
An investigation published in the current issue of Psychotherapy and Psychosomatics indicates how the smartphone may have a potential in the treatment of insomnia.
A new method for detecting abnormalities in unborn children is providing physicians with more information to analyze the results than conventional, microscopic testing, according to two George Washington University researchers.
ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.
› Verified 4 days ago
Ashley Danielle Blazon, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 160 S River Rd, Bedford, NH 03110 Phone: 603-537-1300 Fax: 603-310-0191 | |
Megan E Leonard, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 201 Riverway Pl, Bedford, NH 03110 Phone: 603-668-8400 | |
Mrs. Patricia A Pappal, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 360 Route 101, Unit 10, Bedford, NH 03110 Phone: 603-472-2846 | |
Ms. Amanda Sadat, MA Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 15 Constitution Dr, Suite 1a, Bedford, NH 03110 Phone: 603-310-5026 Fax: 603-218-6187 | |
Sarah Wheeler, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 160 S River Rd, Bedford, NH 03110 Phone: 603-537-1300 Fax: 603-310-0191 | |
Alex Mutuku, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 188 Nh 101, Bedford, NH 03110 Phone: 603-314-4700 | |
Ashley Marie Lougee, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 25 Leavey Dr, Bedford, NH 03110 Phone: 603-472-7233 |